When combined with the observation that a significant number of primary resistant ZEB1‐negative melanomas exhibit high levels of TWIST1 expression, these results suggest that ZEB1 is the main driver of BRAFi resistance, but that TWIST1 may complement ZEB1 when this factor is not activated, and may thus constitute a potential therapeutic target in a subset of melanomas. This evidence concerns the gene TWIST1 and melanoma.